Novanta Inc (NOVT)

Electronics • Information Technology

Stock AI

News & Reports

July 27, 2026 Novanta Inc. Expands Portfolio with Riverpoint Medical Acquisition Novanta Inc. has completed the acquisition of Riverpoint Medical, boosting its revenue potential and market reach in minimally invasive surgical consumables. This strategic move is expected to significantly enhance Novanta's financial performance and growth trajectory in the medical technology sector.

July 14, 2026 Novanta Inc. Announces Second Quarter 2026 Earnings Release and Conference Call Schedule Novanta Inc. is set to release its Q2 2026 earnings on August 5, 2026, followed by a conference call on August 6. This call will provide insights into the company's financial health and strategic initiatives.

June 22, 2026 Novanta Inc. Set to Showcase Innovations at CJS Securities Conference Novanta Inc. will showcase its innovations at the CJS Securities Conference on July 9, 2026. CFO Robert Buckley and COO Chuck Ravetto will discuss strategic initiatives and the company's growth system aimed at enhancing performance and competitive advantage in the medical technology sector.

June 09, 2026 Novanta Inc. Announces $300 Million Private Placement: A Strategic Move to Enhance Capital Structure Novanta Inc. has announced a $300 million private placement of common shares to strengthen its capital structure. This strategic move aims to enhance financial flexibility and support growth opportunities. The offering, set to close soon, reflects Novanta's commitment to proactive capital management.

June 09, 2026 Novanta Inc. Expands Portfolio with Strategic Acquisition of Riverpoint Medical Novanta Inc. is set to acquire Riverpoint Medical for $1.2 billion, aiming to enhance its portfolio in minimally invasive surgical consumables. The deal is expected to double Novanta's medical consumables revenue and significantly improve growth potential.

April 14, 2026 Novanta Inc. Schedules First Quarter 2026 Earnings Release and Conference Call Novanta Inc. will release its Q1 2026 financial results on May 11, 2026, followed by a conference call on May 12. The call will discuss performance insights and future strategies.

March 16, 2026 Novanta Inc. Partners with NVIDIA to Advance AI Systems Safety and Certification Novanta Inc. has partnered with NVIDIA to join the Halos AI Systems Inspection Lab, aiming to enhance safety certifications for AI-driven robotics. This collaboration will streamline integration for OEMs, promoting advanced robotics development and ensuring compliance with safety standards.

February 23, 2026 Novanta Inc. Reports Strong Financial Results for Q4 and Full Year 2025 Novanta Inc. reported strong financial results for Q4 and the full year 2025, with an 8.5% revenue growth in Q4 and a total revenue of $980.6 million for the year. Despite challenges, the company is optimistic about future growth driven by acquisitions and increased customer bookings.

February 23, 2026 Novanta Inc. Reports Strong Performance Amid Economic Challenges in 2025 Novanta Inc. reported a 3.3% revenue growth in 2025, reaching $980.6 million, driven by its medical and advanced industrial markets. Despite facing increased operating expenses, the company remains committed to strategic initiatives and acquisitions to enhance future growth.

January 22, 2026 Novanta Inc. Announces Fourth Quarter 2025 Earnings Release and Conference Call Novanta Inc. is set to announce its Q4 2025 earnings on February 24, 2026, followed by a conference call at 8:00 a.m. ET. This event will provide critical insights into the company's financial health and strategies in the medical technology sector.

December 18, 2025 Novanta Inc. Set to Present at 26th Annual New Ideas for the New Year Investor Conference Novanta Inc. will present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on January 14, 2026. COO Chuck Ravetto will share insights on the company's growth strategies in medical technology and advanced manufacturing, highlighting their commitment to innovation and precision.

December 15, 2025 Novanta Inc. to Showcase Innovations at J.P. Morgan Healthcare Conference Novanta Inc. will present at the J.P. Morgan Healthcare Conference, highlighting its leadership, innovations, and growth strategies in healthcare technology. The event will feature insights from CEO Matthijs Glastra and CFO Robert Buckley, emphasizing Novanta's commitment to customer success and market position.

November 07, 2025 Novanta Inc. Secures $550 Million Through Tangible Equity Units Offering Novanta Inc. announced a $550 million public offering of tangible equity units, aiming to strengthen its balance sheet and fund strategic initiatives. The proceeds will primarily be used for debt repayment, investments, and general corporate purposes.

November 05, 2025 Novanta Inc. Launches $550 Million Tangible Equity Units Offering Novanta Inc. has launched a public offering of 11 million tangible equity units, totaling $550 million, to strengthen its financial standing and fund strategic initiatives. Proceeds will be used for debt repayment and potential investments, showcasing Novanta's proactive approach to market demands.

November 03, 2025 Novanta Inc. Reports Third Quarter Financial Results for 2025 Novanta Inc. reported $247.8 million in Q3 2025 revenue, a slight increase from the previous year, but with declines in operating and net income. CEO Matthijs Glastra emphasized resilience and optimism for future growth amidst challenges, particularly in the Advanced Surgery sector.

November 03, 2025 Novanta Inc. Reports Mixed Results in Q3 2025 as Strategic Initiatives Continue Novanta Inc. reported a 1.4% revenue increase to $247.8 million in Q3 2025, driven by acquisitions, despite a 32.9% decline in operating income. The Medical Solutions segment thrived, while overall expenses rose significantly. Strategic initiatives, including new acquisitions, position the company for future growth.

October 28, 2025 Novanta Inc. Gears Up for Jefferies Global Healthcare Conference Novanta Inc. will participate in the Jefferies Global Healthcare Conference on November 18, 2025. CEO Matthijs Glastra is set to present the company's innovative technology solutions and strategic vision for the medical sector.

October 24, 2025 Novanta Inc. Hosts ISO Event to Establish Humanoid Robot Safety Standards Novanta Inc. is hosting an ISO working group in Barcelona to develop international safety standards for humanoid robots. This initiative aims to address unique safety challenges and promote collaboration among industry experts, ensuring safe human-robot interactions and fostering innovation.

October 21, 2025 Novanta Inc. Set to Showcase Innovations at Baird 2025 Global Industrial Conference Novanta Inc. will showcase its latest innovations at the Baird 2025 Global Industrial Conference on November 11, 2025. CEO Matthijs Glastra will discuss the company’s advancements in technology solutions for medical and industrial sectors, highlighting their commitment to growth and innovation.

October 07, 2025 Novanta Inc. Schedules Earnings Release and Conference Call for Q3 2025 Novanta Inc. is set to release its Q3 2025 earnings on November 4, followed by a conference call at 8:30 a.m. ET. This event will provide crucial insights into the company's performance amid market challenges and opportunities.

August 05, 2025 Novanta Inc. Reports Q2 2025 Results: Strategic Growth Amidst Economic Challenges Novanta Inc. reported a 2.2% revenue increase in Q2 2025, driven by its Automation Enabling Technologies segment and the acquisition of Keonn Technologies. Despite operational challenges and rising expenses, the company remains committed to innovative growth strategies.

May 15, 2025 Novanta Inc. to Showcase Innovations at Baird 2025 Conference Novanta Inc. will present at the Baird 2025 Conference on June 4, showcasing its advancements in precision technology. CFO Robert Buckley will discuss the company's operational strategies and commitment to innovation, highlighting its role in the medical and technology sectors.

May 13, 2025 Novanta Inc. to Present at the William Blair 45th Annual Growth Stock Conference Novanta Inc. will showcase its growth strategies at the William Blair 45th Annual Growth Stock Conference on June 3, 2025. CEO Matthijs Glastra will discuss the company's innovations in medical and industrial technology, emphasizing its commitment to precision and customer success.

May 06, 2025 Novanta Inc. Reports Q1 2025 Financial Results: A Steady Course Amidst Challenges Novanta Inc. reported a modest revenue increase of 1.1% for Q1 2025, with significant growth in operating income. Despite challenges like inflation, the company's strategic restructuring and recent acquisition position it for future success.

May 06, 2025 Novanta Inc. Reports Robust Q1 2025 Financial Results Amidst Economic Challenges Novanta Inc. reported strong Q1 2025 financial results, with revenue of $233.4 million and a 45% increase in net income. The company is well-positioned for future growth amid economic challenges, with proactive strategies in place.

April 08, 2025 Novanta Inc. Schedules Q1 2025 Earnings Release Novanta Inc. has announced its Q1 2025 earnings release date for May 6, 2025, followed by a conference call at 10:00 a.m. ET. A replay of the call will be available for those unable to attend.

March 12, 2025 SWOT Analysis of Novanta Inc in 2025 This SWOT analysis evaluates Novanta Inc.'s position in 2025, highlighting its market leadership and technological advancements while addressing weaknesses like high debt levels and customer dependence. The article also discusses growth opportunities in the medical sector and potential threats from economic uncertainty and competition.

February 25, 2025 Novanta Inc. Reports Strong Financial Performance in 2024 Novanta Inc. achieved a total revenue of $949.2 million in 2024, a 7.7% increase driven by growth in its medical solutions segment. The company remains focused on innovation and strategic acquisitions, positioning itself for future success.

February 25, 2025 Novanta Inc. Reports Robust Financial Performance for Q4 and Full Year 2024 Novanta Inc. reported robust financial results for Q4 and full year 2024, achieving significant revenue growth and increased earnings. The company navigated economic challenges successfully, with a strong focus on cash flow management and future innovation.

November 05, 2024 Novanta Inc. Reports Q3 2024 Financial Results Novanta Inc. reported strong Q3 2024 revenue growth to $244.4 million despite a decrease in net income to $19.19 million, influenced by inflation and geopolitical tensions. The company's strategic acquisition of Motion Solutions aims to enhance its manufacturing capabilities.

August 06, 2024 Novanta Inc. Reports 2024 Q2 Financial Results: Resilience Amid Challenges Novanta Inc.'s Q2 2024 financial results show a 2.8% revenue increase to $235.9 million, driven by strong performance in Medical Solutions. However, inflation and geopolitical uncertainties have impacted operating income and net income. The company remains focused on strategic acquisitions for sustainable growth.

May 07, 2024 Novanta Inc. Reports Q1 2024 Financial Results: A Mixed Bag of Performance Novanta Inc. reported a mixed performance in Q1 2024, with overall revenue increasing to $230.9 million, driven by a 32% rise in Medical Solutions. However, segments like Precision Medicine and Robotics faced declines. The company is focusing on strategic acquisitions and innovation to navigate market complexities.

Novanta Inc. to Showcase Innovations at J.P. Morgan Healthcare Conference

Last updated: December 15, 2025 •

Taurigo

1. Introduction

In a strategic move that underscores its commitment to the healthcare technology sector, Novanta Inc. (Nasdaq: NOVT) has announced its participation in the prestigious J.P. Morgan 44th Annual Healthcare Conference. Scheduled for January 14, 2026, in San Francisco, California, the event will feature key presentations from the company’s leadership, including Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer.

2. Highlighting Leadership at the Conference

The participation of Novanta's top executives at this leading healthcare conference is a testament to the company's proactive approach to engaging with investors and industry stakeholders. Matthijs Glastra and Robert Buckley are expected to share insights into Novanta's strategic direction, technological advancements, and growth initiatives aimed at enhancing the capabilities of medical and advanced technology equipment manufacturers.

3. About Novanta

Novanta Inc. has established itself as a frontrunner in providing core technology solutions tailored for the medical and advanced industrial sectors. The company prides itself on its ability to deliver high-performance components and sub-systems that cater to the demanding requirements of its clients. With a robust focus on innovation, Novanta leverages its proprietary technology expertise across precision medicine, medical solutions, and robotics and automation.

Innovation and Commitment to Customer Success

At the heart of Novanta's success is its dedicated team of professionals who are committed to pushing the boundaries of technology while ensuring customer satisfaction. This commitment to innovation not only sets Novanta apart from its competitors but also positions it as a trusted partner for original equipment manufacturers (OEMs) seeking a competitive edge in their respective markets.

4. Market Position and Future Prospects

As the healthcare technology landscape continues to evolve, Novanta’s role as a key supplier of precision solutions becomes increasingly vital. By participating in the J.P. Morgan Healthcare Conference, Novanta aims to reinforce its market position and outline its future growth strategies, which will likely focus on expanding its technological capabilities and enhancing its service offerings.

5. Conclusion

Novanta Inc.'s upcoming presentation at the J.P. Morgan 44th Annual Healthcare Conference represents a significant opportunity for the company to highlight its innovations and strategic vision for the future. Stakeholders and investors alike will be keen to hear how Novanta plans to navigate the complexities of the healthcare technology sector and leverage its strengths to deliver sustained growth and success. As the date approaches, all eyes will be on the company to see how it articulates its roadmap in this dynamic industry landscape.

Original press release

You may also be interested in: